HER2/neu-Specific Antibodies and Methods of Using Same

摘要

This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.

主权项

1. A method of treating a HER2/neu-expressing cancer in a subject in need thereof, comprising administering to the subject:
a) a first dose of 10, 15, or 18 mg/kg of a chimeric 4D5 antibody; and b) a second dose of 10, 15, or 18 mg/kg of the chimeric 4D5 antibody administered to the subject, wherein the second dose is administered three weeks (±3 days) following the administration of the first dose; wherein the chimeric 4D5 antibody comprises a light chain variable domain having the amino acid sequence of SEQ ID NO:4, and a heavy chain having an amino acid sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:13.